Clinical Trial Update: Pharmacokinetics of Plasma Doravirine Once Daily Over 72 Hours Following Drug Intake Cessation in Healthy Volunteers [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetics study assessing plasma doravirine levels for 72 hours after dosing cessation in healthy volunteers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• PIFELTRO (doravirine)

Snippet

Sponsor: Chelsea and Westminster NHS Foundation Trust | Conditions: Human Immunodeficiency Virus | Phase 1 | Status: COMPLETED | Results posted: 2024-09-19